Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.